Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Fluconazole

FDA-approved product (tablet, oral), marketed as Diflucan, Diflucan In Dextrose 5% In Plastic Container, Diflucan In Sodium Chloride 0.9% and 5 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Fluconazole
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Candidiasis
  • Cryptococcal meningitis
  • Urinary tract infection
  • Vulvovaginal candidiasis

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Imidazole and triazole derivatives; Triazole and tetrazole derivatives
FDA pharmacologic class
Azole Antifungal FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC D01AC15; WHO ATC J02AC01; FDA class Azole Antifungal

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for this infection.

AI-predicted activity

AI prediction · nothing measured
  • MRSA38.7% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • E. coli25.0% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae15.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis58.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Fluconazole in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-7.4 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.0 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.4 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.8 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Fluconazole with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Intrastromal Injection of Fluconazole in Treatment of Fungal Keratitis

    NCT07557966 · start 2022-01-01

    Registered record
    Registry ID
    NCT07557966
    Conditions
    Safety; Efficacy; Intrastromal Injection; Fluconazole; Treatment; Fungal Keratitis
    Interventions
    Topical fluconazole eye drops; Intrastromal injection of fluconazole
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2022-01-01
    Completion
    2022-12-01
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSafety; Efficacy; Intrastromal Injection; Fluconazole +2 more
    InterventionTopical fluconazole eye drops; Intrastromal injection of fluconazole
    PhaseNot applicable
    Registry statusCompleted

  • A Study in Healthy Men to Test How Fluconazole Influences the Amount of BI 425809 in the Blood

    NCT05076409 · start 2021-10-19

    Registered record
    Registry ID
    NCT05076409
    Conditions
    Healthy
    Interventions
    BI 425809; fluconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2021-10-19
    Completion
    2022-01-10
    Enrolment
    15

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionBI 425809; fluconazole
    PhasePhase 1
    Registry statusCompleted

  • A Study to Evaluate the Effect of Pharmacokinetics (PK) of Acalabrutinib and Its Active Metabolite (ACP-5862) When Administered Alone and With Moderate CYP3A4 Inhibitors Fluconazole or Isavuconazole in Healthy Adult Participants

    NCT05140096 · start 2020-01-03

    Registered record
    Registry ID
    NCT05140096
    Conditions
    Healthy Volunteers
    Interventions
    Acalabrutinib; Fluconazole; Isavuconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2020-01-03
    Completion
    2020-04-15
    Enrolment
    30

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionAcalabrutinib; Fluconazole; Isavuconazole
    PhasePhase 1
    Registry statusCompleted

  • Population Pharmacokinetics of Fluconazole in the Treatment of Neonatal Fungal Infectious Disease

    NCT05775692 · start 2020-01-01

    Registered record
    Registry ID
    NCT05775692
    Conditions
    Fluconazole; Infection; Newborn; Pharmacokinetics
    Interventions
    fluconazole
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2020-01-01
    Completion
    2023-12-31
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionFluconazole; Infection; Newborn; Pharmacokinetics
    Interventionfluconazole
    PhaseNot recorded
    Registry statusUnknown

  • A Study of Revumenib in R/R Leukemias Including Those With an MLL/KMT2A Gene Rearrangement or NPM1 Mutation

    NCT04065399 · start 2019-11-05

    Registered record
    Registry ID
    NCT04065399
    Conditions
    Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Mixed Lineage Acute Leukemia; Mixed Phenotype Acute Leukemia; Acute Leukemia of Ambiguous Lineage
    Interventions
    revumenib; cobicistat
    Study type
    INTERVENTIONAL
    Phase
    Phase 1 / Phase 2
    Registry status
    Recruiting
    Start
    2019-11-05
    Completion
    2027-12-15
    Enrolment
    447

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Mixed Lineage Acute Leukemia; Mixed Phenotype Acute Leukemia +1 more
    Interventionrevumenib; cobicistat
    PhasePhase 1 / Phase 2
    Registry statusRecruiting

  • An Evaluation of PCV13 Vaccine Schedules, Comparing Impact of 2+1 vs 3+0 on Pneumococcal Carriage in Blantyre, Malawi

    NCT04078997 · start 2019-07-21

    Registered record
    Registry ID
    NCT04078997
    Conditions
    13-valent Pneumococcal Vaccine; Streptococcus Pneumoniae
    Interventions
    nasopharyngeal swab
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2019-07-21
    Completion
    2024-02-16
    Enrolment
    3,507

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    Condition13-valent Pneumococcal Vaccine; Streptococcus Pneumoniae
    Interventionnasopharyngeal swab
    PhaseNot recorded
    Registry statusCompleted

  • Candida Associated Cytokines in Oral Leukoplakia

    NCT04712929 · start 2018-11-01

    Registered record
    Registry ID
    NCT04712929
    Conditions
    Oral Leukoplakia
    Interventions
    Fluconazole
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Completed
    Start
    2018-11-01
    Completion
    2020-03-30
    Enrolment
    90

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionOral Leukoplakia
    InterventionFluconazole
    PhaseNot recorded
    Registry statusCompleted

  • Pilot Study of Fundamental Modification of the Gut Microbiota in the Treatment of Refractory Crohn's Disease

    NCT03476317 · start 2018-07-12

    Registered record
    Registry ID
    NCT03476317
    Conditions
    Crohn Disease
    Interventions
    Vancomycin; Neomycin; Ciprofloxacin; Polyethylene Glycol 3350; Fluconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2018-07-12
    Completion
    2020-12-31
    Enrolment
    10

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCrohn Disease
    InterventionVancomycin; Neomycin; Ciprofloxacin; Polyethylene Glycol 3350 +1 more
    PhasePhase 2
    Registry statusCompleted

  • Antifungal Drugs in Treatment of Onychomycosis

    NCT03171584 · start 2017-07-01

    Registered record
    Registry ID
    NCT03171584
    Conditions
    Antifungal Drugs in Onychomycosis
    Interventions
    Terbinafine
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2017-07-01
    Completion
    2019-11-01
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAntifungal Drugs in Onychomycosis
    InterventionTerbinafine
    PhasePhase 3
    Registry statusUnknown

  • Study of Potential for Interaction of Fluconazole With F901318

    NCT02730442 · start 2016-02

    Registered record
    Registry ID
    NCT02730442
    Conditions
    Invasive Aspergillosis
    Interventions
    F901318; Fluconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2016-02
    Completion
    2016-06
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionInvasive Aspergillosis
    InterventionF901318; Fluconazole
    PhasePhase 1
    Registry statusCompleted

  • Vietnam Cryptococcal Retention in Care Study - Version 2.1

    NCT03267407 · start 2015-08-14

    Registered record
    Registry ID
    NCT03267407
    Conditions
    HIV/AIDS; Cryptococcal Meningitis; Opportunistic Infections, HIV Related; Cryptococcosis; Mycosis; Opportunistic; Mycosis Fungoides
    Interventions
    Preemptive high-dose Fluconazole
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Unknown
    Start
    2015-08-14
    Completion
    2018-03-31
    Enrolment
    1,184

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHIV/AIDS; Cryptococcal Meningitis; Opportunistic Infections, HIV Related; Cryptococcosis +3 more
    InterventionPreemptive high-dose Fluconazole
    PhaseNot recorded
    Registry statusUnknown

  • Pre-Antiretroviral Therapy (ART) Cryptococcal Antigen Screening in AIDS

    NCT02624453 · start 2015-07

    Registered record
    Registry ID
    NCT02624453
    Conditions
    Cryptococcal Meningitis
    Interventions
    Fluconazole; Antiretroviral therapy
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2015-07
    Completion
    2018-03
    Enrolment
    186

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCryptococcal Meningitis
    InterventionFluconazole; Antiretroviral therapy
    PhaseNot applicable
    Registry statusUnknown

  • Vietnam Cryptococcal Retention in Care Study (CRICS) Federal Financial Report

    NCT02955862 · start 2015-06

    Registered record
    Registry ID
    NCT02955862
    Conditions
    Cryptococcal Meningitis
    Interventions
    Vietnam Cryptococcal Retention in Care Study (CRICS)
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2015-06
    Completion
    2017-09
    Enrolment
    1,177

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCryptococcal Meningitis
    InterventionVietnam Cryptococcal Retention in Care Study (CRICS)
    PhasePhase 1
    Registry statusCompleted

  • Drug-Drug Interaction Study in Healthy Adult Volunteers

    NCT02275975 · start 2014-07

    Registered record
    Registry ID
    NCT02275975
    Conditions
    Healthy
    Interventions
    K-877; Fluconazole
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2014-07
    Completion
    Not recorded
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy
    InterventionK-877; Fluconazole
    PhasePhase 1
    Registry statusCompleted

  • PORH and Response to Cold in Raynaud's Phenomenon.

    NCT02183779 · start 2014-06

    Registered record
    Registry ID
    NCT02183779
    Conditions
    Raynaud Disease; Hyperemia; Cold
    Interventions
    post-occlusive hyperemia; cooling box; L-NMMA and Fluconazole dermic injection
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2014-06
    Completion
    2017-06
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRaynaud Disease; Hyperemia; Cold
    Interventionpost-occlusive hyperemia; cooling box; L-NMMA and Fluconazole dermic injection
    PhaseNot applicable
    Registry statusUnknown